Middle East & Africa Meningococcal Vaccines Market Size & Outlook
Middle East & Africa meningococcal vaccines market, 2018-2030 (US$M)
Related Markets
MEA meningococcal vaccines market highlights
- The MEA meningococcal vaccines market generated a revenue of USD 67.1 million in 2021.
- The market is expected to grow at a CAGR of 8.7% from 2022 to 2030.
- In terms of segment, quadrivalent was the largest revenue generating type in 2021.
- Quadrivalent is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, Morocco is expected to register the highest CAGR from 2022 to 2030.
MEA data book summary
| Market revenue in 2021 | USD 67.1 million |
| Market revenue in 2030 | USD 141.7 million |
| Growth rate | 8.7% (CAGR from 2021 to 2030) |
| Largest segment | Quadrivalent |
| Fastest growing segment | Quadrivalent |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bivalent, Quadrivalent |
| Key market players worldwide | Pfizer Inc, Sanofi SA, GSK PLC, Merck & Co Inc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology |
Other key industry trends
- In terms of revenue, MEA region accounted for 2.3% of the global meningococcal vaccines market in 2021.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- MEA is the fastest growing regional market and is projected to reach USD 141.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Meningococcal Vaccines Market Scope
Meningococcal Vaccines Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa meningococcal vaccines market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to meningococcal vaccines market will help companies and investors design strategic landscapes.
Quadrivalent was the largest segment with a revenue share of 62% in 2021. Horizon Databook has segmented the Middle East & Africa meningococcal vaccines market based on bivalent, quadrivalent covering the revenue growth of each sub-segment from 2018 to 2030.
Major markets in MEA region include South Africa, Saudi Arabia, Turkey, and UAE. Economic development witnessed in emerging markets, such as South Africa, the presence of high unmet healthcare needs, and high incidence of disease are some primary drivers of the market.
Highest incidence rate of meningococcal disease is found in the meningitis belt of sub-Saharan region of Africa. In this region, serogroup A accounted for around 90% of cases. Meningitis Vaccine Project in the region helped increase the vaccine uptake in the African meningitis belt.
Many organizations such as WHO, Agency Medicine Preventive, and Ministries of Health in Africa, among others have collaborated to monitor the evaluation of Men AfriVac impact on the incidence of meningococcal disease.
Reasons to subscribe to Middle East & Africa meningococcal vaccines market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa meningococcal vaccines market databook
-
Our clientele includes a mix of meningococcal vaccines market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa meningococcal vaccines market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa meningococcal vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA meningococcal vaccines market size, by country, 2018-2030 (US$M)
Middle East & Africa Meningococcal Vaccines Market Outlook Share, 2021 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
